Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 44

1.

Underutilization of Statins When Indicated in HIV-Seropositive and Seronegative Women.

Todd JV, Cole SR, Wohl DA, Simpson RJ Jr, Jonsson Funk M, Brookhart MA, Cocohoba J, Merenstein D, Sharma A, Lazar J, Milam J, Cohen M, Gange S, Lewis TT, Burkholder G, Adimora AA.

AIDS Patient Care STDS. 2017 Nov;31(11):447-454. doi: 10.1089/apc.2017.0145.

PMID:
29087746
2.

Evidence-based review of statin use in patients with HIV on antiretroviral therapy.

Chastain DB, Stover KR, Riche DM.

J Clin Transl Endocrinol. 2017 Feb 22;8:6-14. doi: 10.1016/j.jcte.2017.01.004. eCollection 2017 Jun. Review.

3.

Safety and Efficacy of Atorvastatin in Human Immunodeficiency Virus-infected Children, Adolescents and Young Adults With Hyperlipidemia.

Melvin AJ, Montepiedra G, Aaron L, Meyer WA 3rd, Spiegel HM, Borkowsky W, Abzug MJ, Best BM, Crain MJ, Borum PR, Graham B, Anthony P, Shin K, Siberry GK; P1063 Study Team.

Pediatr Infect Dis J. 2017 Jan;36(1):53-60.

PMID:
27749649
4.

HIV and Hepatitis C-Coinfected Patients Have Lower Low-Density Lipoprotein Cholesterol Despite Higher Proprotein Convertase Subtilisin Kexin 9 (PCSK9): An Apparent "PCSK9-Lipid Paradox".

Kohli P, Ganz P, Ma Y, Scherzer R, Hur S, Weigel B, Grunfeld C, Deeks S, Wasserman S, Scott R, Hsue PY.

J Am Heart Assoc. 2016 Apr 29;5(5). pii: e002683. doi: 10.1161/JAHA.115.002683.

5.

Coronary artery disease risk reduction in HIV-infected persons: a comparative analysis.

Okeke NL, Chin T, Clement M, Chow SC, Hicks CB.

AIDS Care. 2016;28(4):475-82. doi: 10.1080/09540121.2015.1099602. Epub 2015 Oct 19.

6.

A Review of the Toxicity of HIV Medications II: Interactions with Drugs and Complementary and Alternative Medicine Products.

Stolbach A, Paziana K, Heverling H, Pham P.

J Med Toxicol. 2015 Sep;11(3):326-41. doi: 10.1007/s13181-015-0465-0. Review.

7.

Rhabdomyolysis after ezetimibe/simvastatin therapy in an HIV-infected patient.

Chanson N, Bossi P, Schneider L, Bourry E, Izzedine H.

NDT Plus. 2008 Jun;1(3):157-61. doi: 10.1093/ndtplus/sfn012. No abstract available.

8.

Impact of antiretroviral therapy on lipid metabolism of human immunodeficiency virus-infected patients: Old and new drugs.

da Cunha J, Maselli LM, Stern AC, Spada C, Bydlowski SP.

World J Virol. 2015 May 12;4(2):56-77. doi: 10.5501/wjv.v4.i2.56. Review.

9.

Parsing interindividual drug variability: an emerging role for systems pharmacology.

Turner RM, Park BK, Pirmohamed M.

Wiley Interdiscip Rev Syst Biol Med. 2015 Jul-Aug;7(4):221-41. doi: 10.1002/wsbm.1302. Epub 2015 May 7. Review.

10.

Managing drug interactions in HIV-infected adults with comorbid illness.

Hughes CA, Tseng A, Cooper R.

CMAJ. 2015 Jan 6;187(1):36-43. doi: 10.1503/cmaj.131626. Epub 2014 Sep 15. Review. No abstract available.

11.

Lack of pharmacokinetic interactions between pitavastatin and efavirenz or darunavir/ritonavir.

Malvestutto CD, Ma Q, Morse GD, Underberg JA, Aberg JA.

J Acquir Immune Defic Syndr. 2014 Dec 1;67(4):390-6. doi: 10.1097/QAI.0000000000000333.

12.
13.

Mg supplementation attenuates ritonavir-induced hyperlipidemia, oxidative stress, and cardiac dysfunction in rats.

Mak IT, Kramer JH, Chen X, Chmielinska JJ, Spurney CF, Weglicki WB.

Am J Physiol Regul Integr Comp Physiol. 2013 Nov 15;305(10):R1102-11. doi: 10.1152/ajpregu.00268.2013. Epub 2013 Sep 18.

14.

HIV stroke risk: evidence and implications.

Singer EJ, Valdes-Sueiras M, Commins DL, Yong W, Carlson M.

Ther Adv Chronic Dis. 2013 Mar;4(2):61-70. doi: 10.1177/2040622312471840.

15.

Clinical pharmacokinetics of antiretroviral drugs in older persons.

Schoen JC, Erlandson KM, Anderson PL.

Expert Opin Drug Metab Toxicol. 2013 May;9(5):573-88. doi: 10.1517/17425255.2013.781153. Epub 2013 Mar 20. Review.

16.

Clinical importance of the drug interaction between statins and CYP3A4 inhibitors: a retrospective cohort study in The Health Improvement Network.

Rowan CG, Brunelli SM, Munson J, Flory J, Reese PP, Hennessy S, Lewis J, Mines D, Barrett JS, Bilker W, Strom BL.

Pharmacoepidemiol Drug Saf. 2012 May;21(5):494-506. doi: 10.1002/pds.3199. Epub 2012 Mar 16.

17.

Drug interaction profile for GSK2248761, a next generation non-nucleoside reverse transcriptase inhibitor.

Piscitelli S, Kim J, Gould E, Lou Y, White S, de Serres M, Johnson M, Zhou XJ, Pietropaolo K, Mayers D.

Br J Clin Pharmacol. 2012 Aug;74(2):336-45. doi: 10.1111/j.1365-2125.2012.04194.x.

18.

Management of dyslipidemia in HIV-infected patients.

Malvestutto CD, Aberg JA.

Clin Lipidol. 2011 Aug;6(4):447-462.

19.

Nutritional and metabolic correlates of cardiovascular and bone disease in HIV-infected patients.

Fitch K, Grinspoon S.

Am J Clin Nutr. 2011 Dec;94(6):1721S-1728S. doi: 10.3945/ajcn.111.012120. Epub 2011 Nov 16. Review.

20.

Management of the metabolic effects of HIV and HIV drugs.

Brown TT, Glesby MJ.

Nat Rev Endocrinol. 2011 Sep 20;8(1):11-21. doi: 10.1038/nrendo.2011.151. Review.

Supplemental Content

Support Center